Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis | medRxiv

CHEERS checklist[supplements/282060_file06.docx]
Supplementary Figure 1[supplements/282060_file07.tif]
Supplementary Figure 2[supplements/282060_file08.tif]
Supplementary Figure 3[supplements/282060_file09.tif]
Supplementary Tables[supplements/282060_file10.docx]

View the discussion thread.

Posted November 10, 2022.

Supplementary Material

Subject Area

Health Economics

Subject Areas

All Articles

Addiction Medicine (404)
Allergy and Immunology (713)
Anesthesia (208)
Cardiovascular Medicine (2973)
Dentistry and Oral Medicine (336)
Dermatology (254)
Emergency Medicine (446)
Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1051)
Epidemiology (12829)
Forensic Medicine (12)
Gastroenterology (834)
Genetic and Genomic Medicine (4627)
Geriatric Medicine (424)
Health Economics (733)
Health Informatics (2946)
Health Policy (1074)
Health Systems and Quality Improvement (1094)
Hematology (394)
HIV/AIDS (935)
Infectious Diseases (except HIV/AIDS) (14153)
Intensive Care and Critical Care Medicine (854)
Medical Education (430)
Medical Ethics (116)
Nephrology (476)
Neurology (4423)
Nursing (238)
Nutrition (653)
Obstetrics and Gynecology (818)
Occupational and Environmental Health (739)
Oncology (2299)
Ophthalmology (654)
Orthopedics (260)
Otolaryngology (327)
Pain Medicine (284)
Palliative Medicine (85)
Pathology (503)
Pediatrics (1201)
Pharmacology and Therapeutics (510)
Primary Care Research (503)
Psychiatry and Clinical Psychology (3812)
Public and Global Health (7014)
Radiology and Imaging (1551)
Rehabilitation Medicine and Physical Therapy (922)
Respiratory Medicine (923)
Rheumatology (446)
Sexual and Reproductive Health (446)
Sports Medicine (386)
Surgery (491)
Toxicology (60)
Transplantation (213)
Urology (185)